Predictive biomarker for hypoxia-activated prodrug therapy
US10760130B2 · kind B2 · utility
0Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 18, 2015 |
| Grant date | Sep 1, 2020 |
| Priority date | — |
| Expiry date | Apr 26, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/7038
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Enolase levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of hypoxia-activated achiral phosphoramide mustards.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.